Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pharvaris N-V stock | $20.5

Learn how to easily invest in Pharvaris N-V stock.

Pharvaris N.V
+$0.31 (+1.88%)

Pharvaris N.V is a biotechnology business based in the US. Pharvaris N-V shares (PHVS) are listed on the NASDAQ and all prices are listed in US Dollars. Pharvaris N-V employs 14 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Pharvaris N-V

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PHVS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Pharvaris N-V stock price (NASDAQ: PHVS)

Use our graph to track the performance of PHVS stocks over time.

Pharvaris N-V shares at a glance

Information last updated 2021-07-28.
Latest market close$20.50
52-week range$13.14 - $42.86
50-day moving average $17.14
200-day moving average $24.32
Wall St. target price$47.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Pharvaris N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pharvaris N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pharvaris N-V price performance over time

Historical closes compared with the close of $20.5 from 2021-05-28

1 week (2021-07-24) N/A
1 month (2021-07-02) 25.77%
3 months (2021-05-04) -17.34%
6 months (2021-01-31) N/A
1 year (2020-07-31) N/A
2 years (2019-07-31) N/A
3 years (2018-07-31) N/A
5 years (2016-07-31) N/A

Pharvaris N-V financials

Gross profit TTM $0
Return on assets TTM -25.69%
Return on equity TTM -45.41%
Profit margin 0%
Book value $7.12
Market capitalisation $562.9 million

TTM: trailing 12 months

Shorting Pharvaris N-V shares

There are currently 114,119 Pharvaris N-V shares held short by investors – that's known as Pharvaris N-V's "short interest". This figure is 77.8% down from 514,756 last month.

There are a few different ways that this level of interest in shorting Pharvaris N-V shares can be evaluated.

Pharvaris N-V's "short interest ratio" (SIR)

Pharvaris N-V's "short interest ratio" (SIR) is the quantity of Pharvaris N-V shares currently shorted divided by the average quantity of Pharvaris N-V shares traded daily (recently around 17449.388379205). Pharvaris N-V's SIR currently stands at 6.54. In other words for every 100,000 Pharvaris N-V shares traded daily on the market, roughly 6540 shares are currently held short.

To gain some more context, you can compare Pharvaris N-V's short interest ratio against those of similar companies.

However Pharvaris N-V's short interest can also be evaluated against the total number of Pharvaris N-V shares, or, against the total number of tradable Pharvaris N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pharvaris N-V's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Pharvaris N-V shares in existence, roughly 0 shares are currently held short) or 0.016% of the tradable shares (for every 100,000 tradable Pharvaris N-V shares, roughly 16 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Pharvaris N-V.

Find out more about how you can short Pharvaris N-V stock.

Pharvaris N-V share dividends

We're not expecting Pharvaris N-V to pay a dividend over the next 12 months.

Pharvaris N-V overview

Pharvaris N. V. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.

Frequently asked questions

What percentage of Pharvaris N-V is owned by insiders or institutions?
Currently 13.131% of Pharvaris N-V shares are held by insiders and 66.561% by institutions.
How many people work for Pharvaris N-V?
Latest data suggests 14 work at Pharvaris N-V.
When does the fiscal year end for Pharvaris N-V?
Pharvaris N-V's fiscal year ends in December.
Where is Pharvaris N-V based?
Pharvaris N-V's address is: J.H. Oortweg 21, Leiden, Netherlands, 2333 CH

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site